Download PDF
TumorDiagnostik & Therapie 2018; 39(09): 581-585
DOI: 10.1055/a-0664-2530
Schwerpunkt Hepatozelluläres Karzinom
© Georg Thieme Verlag KG Stuttgart · New York

Steatohepatitis und Steatohepatitis-getriebener Leberkrebs

Mathias Heikenwälder
Further Information

Publication History

Publication Date:
26 October 2018 (online)

Also available at
    Permissions and Reprints

Kalorienüberschuss und sitzende Lebensweise mit wenig Bewegung haben zu einer globalen Epidemie von Fettleibigkeit geführt. Es gibt zunehmend epidemiologische Hinweise darauf, dass die hepatische Konsequenz – die nicht alkoholische Fettlebererkrankung (NAFLD) – in vielen Fällen für die Entstehung des hepatozellulären Karzinoms (HCC) verantwortlich ist. Wir fassen den aktuellen Stand der Forschung auf diesem Gebiet zusammen.
 

  • Literatur

  • 1 Swinburn BA. et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011; 378: 804-814
    CrossrefPubMedGoogle Scholar
  • 2 Adams LA. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153
    CrossrefPubMedGoogle Scholar
  • 3 Younossi Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018; 15: 11-20
    Google Scholar
  • 4 Bhaskaran K. et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 2014; 384: 755-765
    CrossrefPubMedGoogle Scholar
  • 5 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-1402
    CrossrefPubMedGoogle Scholar
  • 6 Burt AD. et al. Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. Semin Liver Dis 2015; 35: 207-220
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline. Hepatology 2012; 55: 2005-2023
    CrossrefPubMedGoogle Scholar
  • 8 Younossi ZM. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
    CrossrefPubMedGoogle Scholar
  • 9 Buzzetti E. et al. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-1048
    CrossrefPubMedGoogle Scholar
  • 10 Anstee QM. et al. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344
    CrossrefPubMedGoogle Scholar
  • 11 Krenkel O. et al. Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis. Hepatology 2018; 67: 1270-1283
    CrossrefPubMedGoogle Scholar
  • 12 Boyle M. et al. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease. J Hepatol 2018; 68: 251-267
    CrossrefPubMedGoogle Scholar
  • 13 Hart CL. et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. Brit Med J 2010; 340: C1240 10.1136/Bmj.C1240
    CrossrefPubMedGoogle Scholar
  • 14 Singh S. et al. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol 2015; 13: 643-654
    CrossrefPubMedGoogle Scholar
  • 15 Jemal A. et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
    PubMedGoogle Scholar
  • 16 Ascha MS. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
    CrossrefPubMedGoogle Scholar
  • 17 Sanyal A. et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010; 26: 2183-2191
    CrossrefPubMedGoogle Scholar
  • 18 Piscaglia F. et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016; 63: 827-838
    CrossrefPubMedGoogle Scholar
  • 19 Ohnishi S. et al. DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev 2013; 2013: 387014 . doi:10.1155/2013/387014
    PubMedGoogle Scholar
  • 20 Lin R. et al. Chronic inflammation-related DNA damage response: a driving force of gastric cardia carcinogenesis. Oncotarget 2015; 6: 2856-2864
    PubMedGoogle Scholar
  • 21 Boege Y. et al. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer Cell 2017; 32: 342-359
    CrossrefPubMedGoogle Scholar
  • 22 Campisi J. et al. Cellular senescence: when bad things happen to good cells. Nature Rev Molec Cell Biol 2009; 8: 729-740
    PubMedGoogle Scholar
  • 23 Fumagalli M. et al. SASPense and DDRama in cancer and ageing. Nat Cell Biol 2009; 11: 921-923
    CrossrefPubMedGoogle Scholar
  • 24 Nishida N. et al. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31: 1646-1653
    CrossrefPubMedGoogle Scholar
  • 25 Tanaka S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol 2013; 48: 1249-1258
    CrossrefPubMedGoogle Scholar
  • 26 Pascale RM. et al. DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?. DNA Repair 2016; 47: 12-20
    CrossrefPubMedGoogle Scholar
  • 27 Kubes P. et al. Sterile inflammation in the liver. Gastroenterology 2012; 143: 1158-1172
    CrossrefPubMedGoogle Scholar
  • 28 Davis BK. et al. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011; 29: 707-735
    CrossrefPubMedGoogle Scholar
  • 29 Arrese M. et al. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci 2016; 61: 1294-1303
    CrossrefPubMedGoogle Scholar
  • 30 Lanthier N. Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why and how?. World J Hepatol 2015; 7: 2184-2188
    CrossrefPubMedGoogle Scholar
  • 31 Bieghs V. et al. The innate immune response during liver inflammation and metabolic disease. Trends Immunol 2013; 34: 446-452
    CrossrefPubMedGoogle Scholar
  • 32 Shalapour S. et al. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 2017; 551: 340-345
    PubMedGoogle Scholar
  • 33 EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
    CrossrefPubMedGoogle Scholar
  • 34 Heimbach JK. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380
    CrossrefPubMedGoogle Scholar
  • 35 Dyson J. et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117
    CrossrefPubMedGoogle Scholar
  • 36 Taylor EJ. et al. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017; 66: 1546-1555
    CrossrefPubMedGoogle Scholar
  • 37 European Association for the Study of the Liver et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
    CrossrefPubMedGoogle Scholar
  • 38 Bruix J. et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017; 67: 999-1008
    CrossrefPubMedGoogle Scholar
  • 39 Mehnert JM. et al. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 2017; 23: 4970-4979
    CrossrefPubMedGoogle Scholar
  • 40 Ogle LF. et al. Imagestream detection and characterisation of circulating tumour cells – A liquid biopsy for hepatocellular carcinoma?. J Hepatol 2016; 65: 305-313
    CrossrefPubMedGoogle Scholar
  • 41 Mishra SI. et al. Exercise interventions on health-related quality of life for cancer survivors. The Cochrane database of systematic reviews. 2012: CD007566
    PubMedGoogle Scholar
  • 42 Mishra SI. et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. The Cochrane database of systematic reviews. 2012: CD008465
    PubMedGoogle Scholar
  • 43 Gustafson MP. et al. A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. J Immunother Cancer 2017; 5: 30
    CrossrefPubMedGoogle Scholar
  • 44 Idorn M. et al. Exercise: A new role for an old tool. Mol Cell Oncol 2016; 3: e1163005
    PubMedGoogle Scholar
  • 45 Koelwyn GJ. et al. Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer 2017; 17: 620-632
    PubMedGoogle Scholar